Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Theranostics|January 2, 2016
Feasibility of Affibody Molecule-Based PNA-Mediated Radionuclide Pretargeting of Malignant TumorsHadis Honarvar, Kristina Westerlund, Mohamed Altai, et al.
Journal of the American Chemical Society|October 21, 2011
Electrochemical and structural properties of a protein system designed to generate tyrosine Pourbaix diagramsMelissa C Martínez-Rivera, Bruce W Berry, Kathleen G Valentine, et al.
Molecular Pharmaceutics|March 25, 2016
Increasing the Net Negative Charge by Replacement of DOTA Chelator with DOTAGA Improves the Biodistribution of Radiolabeled Second-Generation Synthetic Affibody MoleculesKristina Westerlund, Hadis Honarvar, Emily Norrström, et al.
Protein Engineering, Design & Selection : PEDS|August 30, 2008
Making a single-chain four-helix bundle for redox chemistry studiesKristina Westerlund, Sean D Moran, Heidi K Privett, et al.
Scientific Reports|June 27, 2018
Development of an optimal imaging strategy for selection of patients for affibody-based PNA-mediated radionuclide therapyAnzhelika Vorobyeva, Kristina Westerlund, Bogdan Mitran, et al.
Scientific Reports|November 28, 2020
Evaluation of an antibody-PNA conjugate as a clearing agent for antibody-based PNA-mediated radionuclide pretargetingAnders Myrhammar, Anzhelika Vorobyeva, Kristina Westerlund, et al.
Cancers|February 2, 2021
Comparative Evaluation of Novel 177Lu-Labeled PNA Probes for Affibody-Mediated PNA-Based PretargetingHanna Tano, Maryam Oroujeni, Anzhelika Vorobyeva, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 29, 2021
Affibody-Mediated PNA-Based Pretargeted Cotreatment Improves Survival of Trastuzumab-Treated Mice Bearing HER2-Expressing XenograftsMaryam Oroujeni, Hanna Tano, Anzhelika Vorobyeva, et al.
Nuclear Medicine and Biology|November 13, 2016
Evaluation of the first 44Sc-labeled Affibody molecule for imaging of HER2-expressing tumorsHadis Honarvar, Cristina Müller, Susan Cohrs, et al.
Pharmaceutics|October 21, 2020
Preclinical Evaluation of the GRPR-Targeting Antagonist RM26 Conjugated to the Albumin-Binding Domain for GRPR-Targeting Therapy of CancerAyman Abouzayed, Hanna Tano, Ábel Nagy, et al.
Pageof 3